Generic Name and Formulations:
Riluzole 50mg; tabs.
Covis Pharmaceuticals, Inc.
Indications for RILUTEK:
Amyotrophic lateral sclerosis (ALS).
Take on an empty stomach. 50mg every 12 hours.
Hepatic insufficiency; discontinue if ALT ≥5xULN or if jaundice develops; rechallenge not recommended. Measure LFTs before and during therapy: ALT every month for first 3 months, every 3 months for the remainder of the year, then periodically thereafter. Increased risk of neutropenia; monitor for febrile illness and obtain WBC. Perform chest radiography if respiratory symptoms develop. Females. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with concomitant hepatotoxic agents (eg, allopurinol, methyldopa, sulfasalazine). Avoid excessive alcohol. May be potentiated by CYP1A2 inhibitors (eg, caffeine, phenacetin, theophylline, amitriptyline, quinolones). May be antagonized by CYP1A2 inducers (eg, cigarette smoke, charcoal-broiled food, rifampicin, omeprazole).
Asthenia, nausea, dizziness, decreased lung function, diarrhea, abdominal pain, pneumonia, vomiting, vertigo, circumoral paresthesia, anorexia, somnolence; abnormal liver function tests, neutropenia, interstitial lung disease, hypersensitivity pneumonitis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma